Saturday, November 11th from 9:00am - 9:30am EST
Name
*
First Name
Last Name
Credentials
State Licensed to Practice in
Email
*
example@example.com
Learning Objectives
Poor
Fair
Good
Very Good
Excellent
Review the disease symptom heterogeneity of generalized myasthenia gravis and the rationale for individualized therapy to optimize outcomes through periods of waxing and waning symptom burden
Analyze clinical trial data including real world data for the clinical applications of FcRn and complement inhibitors in the management of gMG
Discuss the effects of individual patient and disease specifics on gMG treatment planning, dosing recommendations, and the management of symptom-free periods
Review the impact of comorbidities on treatment goals and outcomes for patients with gMG
Please provide us with feedback regarding your experience at the activity:
Poor
Fair
Good
Very Good
Excellent
Overall Program
Content
Usefulness
Please rate the faculty on his overall teaching ability:
Poor
Fair
Good
Very Good
Excellent
Gil I. Wolfe, MD
Do you feel this activity was fair balanced and free of commercial bias?
Yes
No
If no, please explain:
This educational activity will result in a change in my role as a healthcare team member.
Yes
No
N/A
Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:
I gained new strategies/skills/information that my team can apply to practice
I plan to implement new strategies/skills/information in my practice
I will be more competent in my team’s management of patient care
I will improve my communication with the healthcare team
What factors beyond clinical care that effect the health of your patients does your team experience?
Submit
Should be Empty: